Get the Stockscreener App
4.97
2.35%
-0.13
Rezolute Inc stock is traded at $4.97, with a volume of 188.26K.
It is down -2.35% in the last 24 hours and down -8.29% over the past month.
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
See More
Previous Close:
$5.10
Open:
$5.08
24h Volume:
188.26K
Relative Volume:
0.42
Market Cap:
$295.51M
Revenue:
-
Net Income/Loss:
$-69.31M
P/E Ratio:
-3.9134
EPS:
-1.27
Net Cash Flow:
$-62.80M
1W Performance:
-5.14%
1M Performance:
-8.29%
6M Performance:
+16.90%
1Y Performance:
+374.29%
1-Day Range:
$4.95
$5.13
1-Week Range:
$4.77
$5.72
52-Week Range:
$0.98
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.975 | 295.51M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.49 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Rezolute Inc (RZLT) Shares Decline Despite Market Challenges - The News Heater
Analytical Overview: Rezolute Inc (RZLT)’s Ratios Tell a Financial Story - The Dwinnex
Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum - Defense World
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally? - MSN
What is the investor’s view on Rezolute Inc (RZLT)? - US Post News
Rezolute (NASDAQ:RZLT) Rating Increased to Strong-Buy at Craig Hallum - MarketBeat
The Attractiveness of Investing In Rezolute Inc (RZLT) is Growing - Knox Daily
H.C. Wainwright reiterates Buy on Rezolute shares, $14 target - Investing.com India
H.C. Wainwright reiterates Buy on Rezolute shares, $14 target By Investing.com - Investing.com South Africa
Rezolute (NASDAQ:RZLT) Given "Buy" Rating at HC Wainwright - MarketBeat
JPMorgan Chase & Co. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Advances SunRIZE Study for Hypoglycemia Treatment - TipRanks
Rezolute's ersodetug advances in pediatric study - MSN
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - Marketscreener.com
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to - EIN News
Rezolute (RZLT) Projected to Post Earnings on Tuesday - MarketBeat
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -February 03, 2025 at 09:06 am EST - Marketscreener.com
(RZLT) Trading Report - Stock Traders Daily
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -January 31, 2025 at 08:01 am EST - Marketscreener.com
Rare Disease Pioneer Rezolute Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Rezolute receives breakthrough therapy designation for treatment of hypoglycemia - MSN
Cantor Fitzgerald Predicts Rezolute FY2025 Earnings - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Resolute Mining (LON:RSG) Stock Price Down 4.1% – Time to Sell? - Defense World
CompoSecure to Spin-Off Resolute Holdings Management - citybiz
CompoSecure Announces Strategic Spin-Off of Resolute Holdings Management, Targets Asset Management Growth - StockTitan
MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat
Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia
Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St
Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World
When the Price of (RZLT) Talks, People Listen - Stock Traders Daily
Rezolute expands authorized shares following shareholder approval - Investing.com
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rezolute Inc Stock (RZLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Evans Daron | CFO |
Dec 12 '24 |
Buy |
4.60 |
9,000 |
41,400 |
140,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
| Hogenhuis Wladimir | Director |
Sep 24 '24 |
Buy |
4.70 |
4,259 |
20,017 |
41,767 |
| Hogenhuis Wladimir | Director |
Jun 25 '24 |
Buy |
4.15 |
4,815 |
19,982 |
37,508 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
4,300 |
16,828 |
54,352 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
3,300 |
12,916 |
13,000 |
| Evans Daron | CFO |
Jun 14 '24 |
Buy |
4.04 |
40,000 |
161,568 |
40,000 |
| Evans Daron | CFO |
May 29 '24 |
Buy |
3.50 |
451 |
1,578 |
121,351 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
May 23 '24 |
Buy |
2.69 |
7,500 |
20,138 |
50,052 |
| Evans Daron | CFO |
May 24 '24 |
Buy |
3.23 |
2,942 |
9,503 |
13,000 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):